Home Oncology Mixed Lilly Trial Findings on Ramucirumab with Cisplatin and Flouropyrimidine as First-Line...

Mixed Lilly Trial Findings on Ramucirumab with Cisplatin and Flouropyrimidine as First-Line Therapy

127
0
Oncology

Although the primary analysis for progression-free survival was statistically significant, this outcome was not confirmed in a sensitivity analysis of progression-free survival by central independent review and did not improve overall survival. Therefore, the addition of ramucirumab to cisplatin plus fluoropyrimidine chemotherapy is not recommended as first-line treatment for this patient population.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.